Table I.
Tumor site | Subjects n (%) |
Gender (% male) |
Age (median, IQR*) |
Stage n (%) |
Lymph node n (%) | Tumour size n (%) |
||
---|---|---|---|---|---|---|---|---|
Oral cavity | 83 (17.2) | 59.0% | 64 (51-71) | 1-2 | 29 (34.9) | 0 (0) | 1 | 11 (13.9) |
2 | 29 (36.7) | |||||||
3-4 | 54 (65.1) | 26 (51.0) | 3 | 10 (12.7) | ||||
4 | 29 (36.7) | |||||||
Missing | 0 (0) | 4 (4.8) | 4 (4.8) | |||||
Oropharynx | 84 (17.4) | 75.3% | 61 (52-68.5) | 1-2 | 31 (36.9) | 0 (0) | 1 | 13 (15.5) |
2 | 32 (38.1) | |||||||
3-4 | 53 (63.1) | 41 (77.4) | 3 | 7 (8.3) | ||||
4 | 32 (38.1) | |||||||
Missing | 0 (0) | 0 (0) | 0 (0) | |||||
Hypopharynx | 20 (4.2) | 65.0% | 61 (58-66) | 1-2 | 1 (5) | 0 (0) | 1 | 1 (5.0) |
2 | 3 (15.0) | |||||||
3-4 | 19 (95) | 14 (73.7) | 3 | 3 (15.0) | ||||
4 | 13 (65.0) | |||||||
Missing | 0 (0) | 0 (0) | 0 (0) | |||||
Larynx | 290 (60.2) | 86.9% | 65 (58-71) | 1-2 | 157 (54.1) | 0 (0) | 1 | 94 (32.4) |
2 | 68 (23.5) | |||||||
3-4 | 133 (45.9) | 47 (35.3) | 3 | 53 (18.3) | ||||
4 | 75 (25.9) | |||||||
Missing | 0 (0) | 0 (0) | 0 (0) | |||||
OC, OP, HP NOS | 5 (1.0) | 80.0% | 64 (51-69) | 1-2 | 3 (60.0) | 1 (33.3) | 1 | 1 (20.0) |
2 | 3 (60.0) | |||||||
3-4 | 2 (40.0) | 2 (100.0) | 3 | - | ||||
4 | 1 (20.0) | |||||||
Missing | 0 (0) | 0 (0) | 0 (0) | |||||
Total | 482 | 79.1% | 64 (57-70) | 1-2 | 221 (45.9) | 0 (0) | 1 | 120 (25.1) |
2 | 135 (28.2) | |||||||
3-4 | 261 (54.2) | 130 (50.4) | 3 | 73 (15.3) | ||||
4 | 150 (31.4) | |||||||
Missing | 0 (0) | 4 (0.8) | 4 (0.8) |
IQR: interquartile range (25°-75° percentile). OC, oral cavity; OP, oropharynx; HP, hypopharynx; NOS, not otherwise specified